Description
Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company has two product candidates, including ZYN002 and ZYN001, which represent cannabinoid therapeutics for several indications, including refractory epilepsy, Fragile X syndrome (FXS), osteoarthritis (OA), fibromyalgia and peripheral neuropathic pain. ZYN002 is a synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. In preclinical animal studies, ZYN002's permeation enhancer increased delivery of CBD through the layers of the skin and into the circulatory system. ZYN001 is a pro-drug of delta-9-tetrahydrocannabinol (THC) that enables transdermal delivery through a patch. In preclinical animal studies, ZYN001 demonstrated effective skin permeation with sustained delivery and rapid conversion of ZYN001 to THC.
Address
80 W. Lancaster Avenue,Suite 300
DEVON, PA 19333
United States
DEVON, PA 19333
United States
Website
http://zynerba.com/Key stats and ratios
| Q1 (Mar '15) | 2014 | |
| Net profit margin | -10060.49% | -699.94% |
| Operating margin | -10065.07% | -699.71% |
| EBITD margin | - | -696.37% |
| Return on average assets | -54.57% | -84.13% |
| Return on average equity | - | - |
| Employees | 7 |
No comments:
Post a Comment